Overview
CellGENTherapies focuses on development and production of small batches of ATMPs, including personalized products and prophylactic RNA vaccines for phase I studies. The company supports UZ Gent, external clients and partners to move research from bench to bedside. CellGENTherapies is a partner in the EU co-funded ATMP XB project and operates new GMP facilities at Ghent University Hospital.
Related profiles
Something wrong or missing? Send an update. Fixed within 24 hours.